Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) which was caught in the “vortex of public opinion” hit the limit and closed down 9.69%. The share price has fallen 30% since its high on April 12
For a longer time, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) since the low of 7.42 yuan at the end of 2019, the stock price has increased by 481%
What funds are behind “making waves” Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) after hours, the data of the one-day list showed that the funds of the dragon and tiger list bought a net 225593 million yuan the Lhasa Business Department of China stock market news, known as the “retail investor base”, is almost exclusive, with seats ranging from buy two to buy five and sell three to sell five Shenzhen Stock connect ranks first in buying and selling seats, buying 251 million yuan and selling 148 million yuan.
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) today responded to the recent public opinion. The company will continue to track the development of the situation. For some acts of publishing false information, the company has retained evidence and reported to relevant departments in addition, the company said on the interactive platform that the media article reported that “the research and development process of Lianhua Qingwen is only 15 days” is inconsistent with the facts . The R & D process of Lianhua Qingwen new drug is the result of the rapid approval of the state in the special epidemic period and the joint efforts of R & D personnel, which is in line with the new drug R & D procedures of the national drug supervision department.
At the media public briefing held in the afternoon, the company’s executives responded to 5 hot public opinion issues such as clinical research, adverse reactions and contraindications of Lianhua Qingwen
about Lianhua Qingwen, no double-blind experiment has been done, Wu Rui said that randomized double-blind multicenter, randomized grouping multicenter and real-world research are all drug clinical evaluation methods recognized by Xi’An International Medical Investment Company Limited(000516) circles. Any of them can be adopted for different diseases, different situations and different stages, and the results are of scientific value. In 2022, Lianhua Qingwen’s randomized, double-blind, international multicenter clinical study on the efficacy and safety of treating mild and moderate covid-19 patients was in progress , and relevant follow-up studies in China were also in progress.
about Lianhua Qing plague is not “COVID-19 pneumonia medication”, Wu Rui said that in April 2020, the State Drug Administration approved that the function of Lianhua Qingwen could be increased in the routine treatment of New Coronavirus pneumonia, it can be used for fever, cough and fatigue caused by light and ordinary type.
about the unclear adverse reactions and taboos of Lianhua Qingwen mentioned in the media articles , the company said that this statement is inconsistent with the facts. Lianhua Qingwen has good safety. According to the data of the national adverse drug reaction monitoring system, the incidence of adverse reactions belongs to the “very rare” level recommended by Xi’An International Medical Investment Company Limited(000516) scientific organization committee (CIOMS).
about who’s “recommended” Lianhua Qingwen, Wu Rui said that after the company’s self-examination, no one in the company has accepted the two media interviews mentioned in the video released by a microblog from the media, nor said on any occasion that the who “recommended” Lianhua Qingwen.
does Jia Zhenhua, as a co-author of relevant clinical research papers, affect the research results Professor Wu Zhenhua was not responsible for the research results and did not participate in any statistical analysis. The clinical trial was a prospective, randomized controlled, multicenter evidence-based study jointly completed by 23 hospitals in 9 provinces, ensuring the objectivity and scientificity of the clinical study.
Public information shows that Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) ‘s main products include cardiovascular, respiratory, diabetes and tumor drugs. Among them, Lianhua Qingwen capsule is the trump card product of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) , and the first half of 2021, the annual sales of Lianhua Qingwen products is about 2 billion 492 million yuan, accounting for 42.3% of total revenue and over 40%.
In 2020, the emergence of covid-19 epidemic situation, is a boost to both the traditional Chinese medicine industry and Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) for after the outbreak of China’s COVID-19 epidemic, in January 27, 2020, the National Health Protection Committee issued the New Coronavirus pneumonia diagnosis and treatment plan (trial version fourth).
Also in that year, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) performance was strong, and the net profit doubled from 606 million yuan in 2019 to 1.218 billion yuan in 2020. Meanwhile, the revenue of respiratory products including Lianhua Qingwen capsules / granules increased from 1.703 billion yuan in 2019 to 4.256 billion yuan in 2020, with a year-on-year increase of 149.89%
In recent years, the market share of Lianhua Qingwen in the Chinese patent medicine cold medicine market of hospital channel and retail channel has gradually increased. After it was approved for covid-19 pneumonia treatment in 2020, the sales and market share of Lianhua Qingwen increased significantly , and has become a leading brand in the field of Chinese patent medicine cold medicine.
The diagnosis and treatment plan for New Coronavirus pneumonia (Trial fifth / six / seven / 8 edition) continues to list Lianhua Qingwen as the recommended medicine during the medical observation period of Chinese medicine. In this year’s New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth), we also classified Lianhua Qingwen as a clinical treatment (confirmed case) with light and general recommendation.
Sinolink Securities Co.Ltd(600109) Wang ban and other analysts said in the research report released on March 28, 2022 that from 2022 to 2023, it is expected that the large volume of overseas market, the growth of patients with mild and moderate diseases in China during the observation period, as well as the potential self provided demand of residents will become the new growth point of Lianhua Qingwen it is estimated that the sales of Lianhua Qingwen will reach 4.3 billion yuan and 4.7 billion yuan from 2022 to 2023
